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Abstract  
Objective: This study aimed to investigate whether HLA-DQA1 and HLA–DQB1 alleles and haplotypes are 
associated with progression of HBV infection to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) in 
HBV infected patients. Methods: Genotyping of the HLA-DQ variants were carried out in 121 HBV patients 
(including 52 HBV without LC/HCC and 69 HBV with LC/HCC), using a polymerase chain reaction 
amplification with sequence specific oligonucleotide (PCR-SSO) technique and Luminex profiling system. 
Results: The two highest allele frequencies were seen for HLA-DQA1*01 and HLA-DQB1*03. A total of 66% 
of the HBV patients with LC/HCC and 62% of HBV patients without LC/HCC are carriers of HLA-DQA1*01 
(p value= 0.908, OR= 0.95, CI= 0.41 - 2.10). As for HLA-DQB1*03, 73% of the HBV patients with LC/HCC 
and 60% of HBV patients without LC /HCC are carriers of this allele (p value= 0.320, OR= 1.56, CI= 0.65 - 
3.72). In addition, 62% of HBV patients with LC/HCC (n=32) and 48% of HBV patients without LC/HCC 
(n=25) were carriers of haplotype DQA1*01-DQB1*05 (p value= 0.495, OR= 0.76, CI= 0.34 - 1.68). 
Conclusion: no association was seen between the HLA-DQA1 and the HLA–DQB1 alleles and haplotypes with 
HBV disease progression in the Malaysian population.   
Keywords: HLA-DQ genotyping; HBV infection; PCR-SSO technique; liver cirrhosis; HCC. 
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1. Introduction  
Hepatitis B virus (HBV) infection is a major public health problem affecting around two billion people globally 
[1]. Among individuals with persistent HBV infection, 10%-30% develop some form of liver disease such as 
liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [2]. HCC is the third leading cause of cancer death in 
the world with more than 600,000 individuals affected [3] while Asian countries account for almost 78% of the 
HCC reported death globally [4]. Besides HBV infection and liver cirrhosis, other factors such as old age, male 
gender, ethnicity and host genetic factors such as the immune system are involved in predisposition to HCC [4]. 
Evidence has shown that host immune mechanisms influence the outcome of HBV infection [5] as well as 
persistence of the viral infection [6].  
Human leukocyte antigen (HLA) is an important component of the immune response and plays a vital role 
against virus infection and tumor resistance. The HLA class II molecules are presented on antigen presenting 
cells including B cells, dendritic cells, thymic epithelial cells, macrophages and activated T cells. The 
recognition of the presented antigens to CD4+ T cells leads to the secretion of cytokines and differentiation of T 
cells [7]. The HLA molecules are located on the chromosome 6p21[8] and contain the highest genetic variations 
in the human genome which is associated with the function of the immune system [7, 8]. The polymorphism in 
HLA class II gene are known to affect the ability of antigen presentation as well as cytokines production [9].  
Recent studies have shown the associations between HLA class II alleles with susceptibility to HBV infection as 
well as vaccine responsiveness and clearance of the HBV virus[10, 11]. To date, several studies have been 
conducted to investigate the association between HLA class II alleles and hepatitis B infection outcomes. Most 
of the findings are related to HLA-DR and HLA-DP alleles. For instance, it has been reported that HLA-
DRB1*07 is associated with HBV persistence in various Asian populations [12, 13]. Moreover, it has been 
shown that HLA- DRB1*1301 is associated with clearance of HBV among different populations [14, 15]. 
Recently a study revealed association between a new protective allele named HLA-DPB1*02:01 as well as a 
new risk allele HLA-DPB1*09:01 with HBV disease in the Asian population[16]. However, there are a few 
studies regarding the association between HLA-DQ alleles and consequences of HBV infection. Thus, this study 
aims to investigate the possible association between HLA-DQ alleles and progression of HBV infection in the 
Malaysian population.  
2. Materials and Methods 
2.1 Subjects 
A total of 121 HBV chronically infected patients (76 males and 45 females) were enrolled in this study. Of 
them, 52 were diagnosed with chronic hepatitis B (CHB) without liver cirrhosis / HCC and 69 CHB with liver 
cirrhosis / HCC. The diagnosis of chronic hepatitis B was confirmed by persistence of HBsAg in excess of six 
months. Presence of liver cirrhosis amongst the chronic hepatitis B infected patients were confirmed by liver 
biopsies, clinical, biochemical or radiological indication of cirrhosis[17] . Diagnoses of HCC were based on the 
radiological evidence of liver mass with arterial hypervascularity and washout in the venous-delayed phase on 
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dynamic imaging and/or by liver histology [18]. All patients were negative for other potential causes of liver 
disease such as Wilson’s disease, hepatitis C infection, primary biliary cirrhosis, autoimmune hepatitis, 
hemochromatosis and alpha-1 anti-trypsin deficiency. Written informed consent was obtained from all 
participants. Ethnicities of the subjects were confirmed by self-report. The study protocol, MEC Ref. No: 
938.42, was approved by the medical ethics committee of the University Malaya Medical Centre (UMMC).   
2.2 Sample collection 
Venous blood from all patients were collected in EDTA tubes. The genomic DNA was extracted from buffy 
coat using the GeneAll@ ExgeneTM DNA purification kit (Dongnam-ro, Songpa-gu, Seoul, South Korea) 
according to the manufacturer’s instructions.   
2.3 HLA-DQA1 / -DQB1 genotyping       
A low resolution (2-digit) genotyping was used to determine the HLA-DQA1 and HLA-DQB1 genotypes in 
CHB patients with and without cirrhosis/HCC. LAB Type polymerase chain reaction amplification (PCR) with 
sequence specific oligonucleotide (PCR-SSO) probes technique together with HLA DQA1/DQB1 One Lambda 
kit (Canoga Park, California, USA) and a Luminex profiling system (xMAP; Luminex, Austin, TX) were used 
for genotyping according to the manufacturer’s protocol.  
The samples were used in final DNA concentration of 20 ng/µl and was considered of good quality if 
absorbance of 260/280 <1.80 and >1.65. Briefly, the target DNA was amplified with biotinylated specific 
primers for the purpose of detection by R-Phycoerythrin conjugated Streptavidin (SAPE).  
The amplified DNA was then denatured, neutralized and hybridized with the oligonucleotide probes which are 
labelled with SAPE and finally detected by Luminex 200 system.  
The HLA alleles were recognized by HLA visual 1.0 software via referring to HLA typing pattern data for -
DQA1 and -DQB1 provided by manufacturer. 
2.4 Statistical analysis 
Allele frequencies of HLA-DQA1 and -DQB1 were calculated using the direct counting method. A chi-square 
test was done to examine deviation from Hardy-Weinberg equilibrium using SPSS version 16.0. Logistic 
regression was applied to conclude the association between HLA-DQA1 and -DQB1 with disease progression in 
CHB patients.  
The Linkage Disequilibrium of two locus haplotype was calculated using the SPSS version 16.0. Odd ratios 
(ORs) with 95% confidence intervals (CI) were calculated after adjustment for confounding factors such as sex 
and age. The data were presented as percentage or mean ± standard deviation.  
A p-value less than 0.05 was considered to be statistically significant. The significance levels for α was set 
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according to the number of observed alleles at each locus. For HLA-DQA1 and -DQB1 alleles, the number of 
observed alleles was 5 for each of them. Thus, the significant levels for HLA-DQA1 and -DQB1 alleles were set 
at α=0.05/5 after Bonferroni correction. 
3. Results 
Demographic information of the 121 study subjects is presented in Table 1. Participants were made up of 44 
who were of the Malay ethnic group and 77 were Chinese. Data from these two ethnicities were pooled to reveal 
the presence of five HLA-DQA1 alleles (-DQA1*01, -DQA1*02, -DQA1*03, -DQA1*05 and -DQA1*06) and 
five HLA-DQB1 alleles (-DQB1*02, -DQB1*03, -DQB1*04, -DQB1*05 and -DQB1*06).  
Table 1: Demographic data of participants for HLA typing. 
  
 
HBV infected without 
LC / HCC (n= 52) 
HBV infected with     
LC / HCC (n= 69) 
p value 




Malay 22 (42.3%) 22 (31.8%) 
 
Chinese 30 (57.7%) 47 (68.2%) 
 





Male 30 (57.7%) 46 (66.7%) 
 
Female 22 (42.3%) 23 (33.3%)   
             LC: liver cirrhosis; HCC: hepatocellular Carcinoma 
             P <0.05 was considered significant 
 
The allele frequencies of HLA-DQA1 and HLA-DQB1 and their associations with progression of HBV disease 
are presented in Table 2. The two highest allele frequencies are seen with HLA-DQA1*01 and HLA-DQB1*03. 
A total of 66% of the HBV patients with cirrhosis / HCC (n=46) and 62% of the HBV patients without cirrhosis 
/ HCC (n=32) are carriers of HLA-DQA1*01 (p value= 0.908, OR= 0.95, CI= 0.41 - 2.10).  
In addition, 73% of HBV patients with cirrhosis / HCC (n=50) and 60% of HBV patients without cirrhosis / 
HCC (n=31) are carriers of HLA-DQB1*03 (p value= 0.320, OR= 1.56, CI= 0.65 - 3.72). Furthermore, 17% of 
HBV patients with cirrhosis / HCC (n=12) and 8% of HBV patients without cirrhosis / HCC (n=4) are carriers 
of HLA-DQA1*02 (p value= 0.167, OR= 2.49, CI= 0.68 - 8.05).  
Whereas 4% of HBV patients with cirrhosis / HCC (n=3) and 12% of HBV patients without cirrhosis / HCC 
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(n=6) were carries HLA-DQB1*04 (p value= 0.455, OR= 0.55, CI= 0.12 - 2.61). There were no significant 
association between any of the HLA alleles studied with progression of CHB to cirrhosis/ HCC. 
The DQA1-DQB1 haplotypes frequencies and their associations with progression of HBV disease are presented 
in Table 3. Twenty-five HLADQA1-DQB1 haplotypes were identified among CHB patients with and without 
cirrhosis/HCC.  
In this study, 62% of HBV patients with cirrhosis/HCC (n=32) and 48% of HBV patients without cirrhosis/HCC 
(n=25) were carriers of haplotype DQA1*01-DQB1*05 (p value= 0.495, OR= 0.76, CI= 0.34 - 1.68). None of 
the haplotypes were significantly associated with progression of HBV infection. 
 
Table 2: The allele frequencies and association of HLA-DQA1/-DQB1 with disease progression in CHB 
patients with and without cirrhosis/HCC. 
Allele  
HBV infected without 
cirrhosis/HCC (n= 52) 
HBV infected with 
cirrhosis/HCC (n= 69) 
  (X₂) OR (95%) p Value  
DQA1     Count          %        Count      %       
01 32          62% 46          66% 0.560 0.95 (0.41 - 2.10) 0.908 
02 4             8% 12          17% 0.119 2.49 (0.68- 8.05) 0.167 
03 22           42% 24          35% 0.399 0.88 (0.39 - 2.01) 0.773 
05 12           23% 20          29% 0.466 1.58 (0.64 - 3.87) 0.319 
06 13           25% 24          35% 0.248 1.18 (0.49 - 2.85) 0.709 
DQB1 
  
   02 9            17% 21          30% 0.096 2.28 (0.87 - 6.01) 0.098 
03 31          60% 50          73% 0.137 1.56 (0.65 - 3.72) 0.320 
04 6            12% 3              4% 0.136 0.55 (0.12 - 2.61) 0.455 
05 25          48% 31           45% 0.731 0.74 (0.33 - 1.63) 0.449 
06 10           19% 18           26% 0.376 1.21 (0.47 - 3.05) 0.695 
 
X2: Pearson Chi Square p value and OR were calculated in presence versus absence of each allele. Association 
of HLA-DQA1 and –DQB1 alleles with HBV disease progression assessed by logistic regression analysis 
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Table 3: The associations of DQA1-DQB1 haplotypes with disease progression in CHB patients with and 
without cirrhosis/HCC. 
Haplotype HBV infected without cirrhosis/HCC (n= 52) 
HBV infected with 
cirrhosis/HCC (n= 69)   (X
₂) OR (95%) p Value  
HLA-DQA  HLA-DQB1     Count    ( %) Count       (%)      
              01      02  4             (7.7) 10             (14.5) 0.247 1.70 (0.45 - 6.50) 0.437 
01      03 13           (25) 28             (40.6) 0.073 1.38 (0.58 - 3.30) 0.469 
01      04 2             (3.8) 1               (1.5)    0.401 0.37 (0.03 - 5.37) 0.464 
01      05 25           (48.1) 32             (61.5) 0.853 0.76 (0.34 - 1.68) 0.495 
01      06 10           (19) 18             (26) 0.376 1.21 (0.48 - 3.05) 0.695 
02      02 4             (7.7) 11             (15.9) 0.173 2.02 (0.55 - 7.40) 0.289 
02      03 1             (1.9) 8               (11.6) 0.045 4.64 (0.86 - 6.37) 0.066 
02      04 0              0 1               (1.5) - - NA 
02      05 2             (3.8) 2               (2.9) 0.773 0.503 (0.06 - 4.12) 0.522 
02      06 0              0 1               (1.5)  - - NA 
03      02 3             (5.8) 5               (7.2) 0.746 1.69 (0.32 - 6.97) 0.536 
03      03 19           (36.5) 23             (33.3) 0.714 1.05 (0.45 - 2.43) 0.916 
03      04 6             (11.5) 3               (4.3) 0.136 0.55 (0.12 - 2.61) 0.455 
03      05 3             (5.8) 3               (4.3) 0.721 0.75 (0.13 - 4.25) 0.745 
03      06 1             (1.9) 9               (13) - - NA 
05      02 5             (9.6) 11             (15.9) 0.309 2.39 (0.69 - 6.21) 0.168 
05      03 9             (17.3) 12             (17.4) 0.99 1.14 (0.41 -3.21) 0.804 
05      04 2             (3.8) 0                  0 - - NA 
05      05 4             (7.7) 9               (13) 0.347 1.81 (0.48 - 4.82) 0.384 
05      06 4             (7.7) 3               (4.3) 0.435 0.53 (0.11 - 2.49) 0.419 
06      02 1             (1.9) 5               (7.2) 0.182 5.30 (0.47 - 5.77) 0.177 
06      03 13           (25) 24             (34.8) 0.248 1.18 (0.49 - 2.85) 0.709 
06      04 2             (3.8) 1               (1.5)  0.401 0.53 (0.04 - 6.52) 0.619 
06      05 5             (9.6) 9               (13) 0.559 0.81 (0.22 - 2.88) 0.738 
06      06 0              0  2               (2.9) - - NA 
X2: Pearson Chi Square p value and OR were calculated in presence versus absence of each allele. Association 
of HLA-DQA1 and –DQB1 alleles with HBV disease progression assessed by logistic regression analysis 
adjusted for gender and age. NA: not applicable. 
4. Discussion and Conclusion 
Evidence has shown the association of HLA Class II molecules with susceptibility or persistence of infectious 
disease [7] such as hepatitis B infection [19]. HLA-DQ is heterodimeric molecule consisting of two 
polypeptides alpha and beta chains which are encoded by HLA-DQA1 and HLA-DQB1 respectively. HLA-DQ 
is highly polymorphic particularly in exon 2 which codes for antigen binding sites. Thus, high variations in this 
region lead to the existence of a number of alleles which are associated with outcome of HBV infection [20]. It 
has been shown that the presence of particular HLA class II alleles influence the effectiveness of the immune 
response to infection [21]. The highly polymorphic HLA genes are main factors in the triggering of the immune 
response against hepatitis B infection through their enormous ability of attracting and binding of hepatitis B 
viral peptides.  
With regard to HBV infection, HLA as a vital element of immune system has been known to influence the 
outcomes of disease. Several studies indicated the association of HLA–DQA1 and –DQB1 alleles with HBV 
 American Scientific Research Journal for Engineering, Technology, and Sciences (ASRJETS) (2018) Volume 43, No  1, pp 159-168 
165 
 
infection outcomes in different populations. For instance, Jiang and his colleagues have conducted a study in 
Chinese Han population among three groups of patients, namely, those with chronic hepatitis B, with acute 
hepatitis B and on healthy controls subjects. Results of the study showed that HLA–DQB1*0301 and HLA–
DQA1*0501 are significantly associated with predisposition to chronic hepatitis B while HLA–DQA1*0301 is 
closely linked to resistance to chronicity of HBV infection [22]. In another study conducted in African 
Americans by Thio and his colleagues it was demonstrated that two HLA alleles, HLA–DQB1*0301 and HLA–
DQA1*0501 as well as their corresponding haplotypes are associated with HBV persistence [23]. In a study by 
Mbarek and his colleagues that was conducted on CHB patients and on non-HBV controls, it was revealed that 
HLA-DQA1*0102–DQB1*0604 and HLA-DQA1*0101–DQB1*0501 are protective haplotypes while HLA-
DQA1*0102–DQB1*0303 and HLA-DQA1*0301–DQB1*0601 are risk haplotypes in the Japanese population 
[19]. Furthermore, some studies from China have revealed that the HLA-DQB1*03:03 and DQB1*05:03 are 
associated with HBV viral persistence [24, 25]. In two other studies from Turkey, it was shown that DQ3 allele 
was related to predisposition to chronic hepatitis B infection [26]. Furthermore, DQB1*05:01 allele is more 
common in chronic active HBV than in inactive patients indicating that the allele is associated with chronic 
HBV persistence [27]. However, the majority of these studies focused on clearance and persistence of HBV 
infection and there are only a few reports on the effect of HLA-DQ alleles on HBV progression to cirrhosis and 
HCC. For instance, HLA-DQA1*0104 was identified as a protective allele in progression to liver cirrhosis [28]. 
A recent meta-analysis has investigated the association between HLA-DQB1 alleles and HCC, and it was 
reported that HLA-DQB1*02 and HLA-DQB1*0502 are risk factors for HCC occurrence whereas DQB1*03 
and HLA-DQB1*0602 have protective effects on HCC [29].      
Our study is the first to demonstrate the prevalence of HLA-DQA1 and -DQB1 alleles and haplotypes in HBV 
infected patients in the Malaysian population. We found that 66% of HBV patients with cirrhosis / HCC and 
62% of HBV patients without cirrhosis / HCC are carriers of HLA-DQA1*01. In addition, 73% of HBV patients 
with cirrhosis / HCC and 60% of HBV patients without cirrhosis / HCC are carries of HLA-DQB1*03. We 
could not find any association between HLA-DQA1 and HLA–DQB1 allele / haplotype and HBV disease 
progression in the Malaysian population. However, the relationship between HLA polymorphism, ethnicity and 
immune response is still unclear, hence further investigation is needed to provide more insight into the role of 
HLA-DQA1 and –DQB1 in the pathogenesis of cirrhosis and HCC.   
Understanding the role of HLA-DQ in immune response in defense of HBV infection can lead to effective 
design of novel immune therapies. Given the inconclusive result of previous studies, further association studies 
with much larger sample size with regard to progression of HBV to cirrhosis and HCC, and HLA-DQ alleles are 
required to provide strategies for the management and prevention of chronic HBV infection.  
5. Limitation of the study 
A larger sample size and additional ethnically diverse samples are required to confirm these findings. 
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